Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies

作者
Lior Fuchs,Ifat Vigiser,Hadar Kolb,Keren Regev,Vivian E. Drory,Amir Dori,David Magalashvili,Tal Caller,Gilad Kenan,Yana Mechnik Steen,Mark Andrew Hellmann,Adi Wilf‐Yarkoni,Tal Friedman Korn,Adi Vaknin‐Dembinsky,Alaa Bsoul,Shahar Shelly,Arnon Karni
出处
期刊:Neurotherapeutics [Springer Science+Business Media]
卷期号:23 (1): e00837-e00837 被引量:8
标识
DOI:10.1016/j.neurot.2026.e00837
摘要

Efgartigimod is an established therapy for acetylcholine receptor antibody-positive generalized myasthenia gravis, yet real-world data on long-term overall responsiveness, response patterns, steroid-sparing effects, bridging therapy use, and predictors of benefit remain limited. In this multicenter retrospective study, we evaluated 46 patients treated across seven tertiary centers between April 2022 and March 2025, collecting demographic, clinical, therapeutic, and outcome data. Patients received 193 treatment cycles (mean 4.3 per patient) with a mean inter-cycle interval of 9.8 weeks. Following the first cycle, 86.9 % achieved a ≥2-point improvement in the Myasthenia Gravis Activities of Daily Living scale and 43.5 % reached minimal symptom expression (MSE); overall, 52.2 % achieved MSE at least once during follow-up. Nonetheless, 35.9 % discontinued efgartigimod due to insufficient efficacy, underscoring heterogeneous and often non-durable responses. Among 29 patients on prednisone, 58.6 % achieved a significant dose reduction (30.9-16.8 mg/day, p = 0.001), with shorter disease duration predicting successful tapering. Bridging therapy was successful in 5 patients, particularly those receiving azathioprine or mycophenolate (p = 0.040), supporting its utility during transitions to slower-acting immunosuppressants. Adverse events occurred in 21.7 % of patients, were generally mild, and led to discontinuation in only one case. Overall, efgartigimod was effective and well tolerated, but treatment responses varied, and cycle-based regimens frequently failed to sustain benefit. The observed steroid-sparing effect and predictors of response highlight the need for personalized treatment strategies and prospective studies to refine long-term use and optimize patient selection.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
万能图书馆的应助被Jayh4n采纳,获得10
1秒前
1秒前
2秒前
小羊有个山完成签到,获得积分10
2秒前
OSBORN发布了新的文献求助30
3秒前
小七发布了新的文献求助10
3秒前
英姑的应助被明理谷兰采纳,获得10
4秒前
1531811发布了新的文献求助10
4秒前
4秒前
NJY发布了新的文献求助10
4秒前
Jasper的应助被神冕星河游采纳,获得10
6秒前
152455发布了新的文献求助10
6秒前
Owen的应助被无语的映采纳,获得10
7秒前
7秒前
灵巧小笼包完成签到 ,获得积分10
7秒前
7秒前
1467664完成签到 ,获得积分20
7秒前
momo完成签到 ,获得积分10
8秒前
8秒前
饱满语风完成签到 ,获得积分10
9秒前
9秒前
慕青的应助被munire采纳,获得10
9秒前
感动的穆发布了新的文献求助10
11秒前
11秒前
赵22222222完成签到 ,获得积分10
11秒前
科研通AI6.2的应助被小白采纳,获得10
12秒前
默默航空完成签到,获得积分10
12秒前
榆楦完成签到 ,获得积分10
12秒前
淡淡丹妗完成签到,获得积分10
12秒前
秀丽的盼旋完成签到,获得积分20
12秒前
李爱国的应助被谨慎的秋烟采纳,获得10
13秒前
领导范儿的应助被cjmlslddjd采纳,获得10
13秒前
14秒前
顺利的访琴的应助被1531811采纳,获得30
14秒前
14秒前
morena的应助被1531811采纳,获得10
14秒前
lmhytr发布了新的文献求助10
15秒前
lin发布了新的文献求助10
15秒前
完美的紊发布了新的文献求助10
16秒前
sufu_jony的应助被胡萝卜卜采纳,获得10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Markov Decision Processes and Reinforcement Learning 700
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8170866
求助须知:如何正确求助?哪些是违规求助? 9563691
关于积分的说明 21771699
捐赠科研通 7762353
什么是DOI,文献DOI怎么找? 3430767
关于科研通互助平台的介绍 2554622
邀请新用户注册赠送积分活动 2475597